Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.

Inclusion Criteria:

• - person who has given their non-opposition to inclusion
• adult
• Healthy volunteers or controls (patients seen in consultation, without history of hemmorhage, etc.).

or

• patients with acute bleeding: polytraumatized, or hemorrhage or intracerebral haemorrhage, or bleeding complications at the end surgery (in particular cardiac surgery with ECMO) or
• patients with antiplatelet therapy or
• patients with thrombocytopenia/thrombopathy

Exclusion Criteria:

• protected adults (curatorship, guardianship)
• person deprived of their liberty by judicial or administrative decision
• pregnant, parturient or breastfeeding woman
• person unable to express their non-opposition
• platelet transfusion on initial management

Patients coming for a consultation at the Resouce Centre for Haemorrhagic Diseases and Coagulopathies in the Internal Medicine and Haematology Department. Patients admitted to the Emergency Department, and patients admitted to the operating theatre by the Surgical Intensive Care Unit, the Neurovascular Emergency Department, or the Neurosurgery Department.